Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15500MR)

This product GTTS-WQ15500MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15500MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15013MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ1820MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ2055MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ5853MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ4396MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ3039MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ2069MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ2555MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW